Search results
Results from the WOW.Com Content Network
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. [4] The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). [ 4 ]
Apremilast, a phthalimide derivative that was approved by the U.S. FDA in March 2014 for use as a treatment for psoriatic arthritis, [21] and in September 2014 for the treatment of plaque psoriasis under the brand name Otezla.
In August 2019, Amgen announced it would acquire the Otezla drug programme from Celgene for $13.4 billion, ... generic, version of thalidomide to market. In response ...
“In 2011, 73% of generic medications covered in Medicare Part D were placed on Tier 1, where cost-sharing [by beneficiaries] averages out to zero. In 2021, that dropped to 15%,” says Sargent.
Sanders said he spoke to the chief executives of several major generic drugmakers over the past few months. US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month ...
Two women, each claiming to have suffered severe medical complications from a generic version of metoclopramide, lost their Supreme Court appeal on June 23, 2011. In a 5–4 ruling in PLIVA, Inc. v. Mensing , [ 70 ] [ 71 ] the court held that generic companies cannot be held liable for information, or the lack of information, on the originator ...
Generic medications contain the same active ingredients as brand-name drugs, but they’re sold under the active ingredient name instead. There isn’t a generic version of Ozempic yet.
Rank Year Purchaser Target Value (in billions USD) Value (adjusted for inflation) 1 2015 Pfizer: Allergan, plc: 160 206 In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation).